Ketmookda Trairat

发表

Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

Ana C. Matos, C. Königs, C. Giaquinto, 2022, The lancet. HIV.

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

Ana C. Matos, C. Königs, J. Seeley, 2022, The lancet. HIV.

Sexually transmitted infections and HIV RNA levels in blood and anogenital compartments among Thai men who have sex with men before and after antiretroviral therapy: implication for Treatment as Prevention programme

P. Phanuphak, N. Teeratakulpisarn, P. Chamnan, 2018, Journal of the International AIDS Society.